Follow The Filings

CYTK Cytokinetics Inc.

Health Care, filed as CYTOKINETICS INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 3 Owners
  • Max 2.8%
  • $18M
  • 2 reduce

In 2026 Q2 Nathan Fischel and Ron Baron trimmed Cytokinetics.

Who owns this now

Largest portfolio weights among holders, up to 2.8% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 2.8%
  2. Palo Alto Investors 0.38%

Who owns CYTK

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 2.8%, was 3.3% Reduce −20.9% 171,998 $15M History
Palo Alto Investors 0.38% Hold 32,195 $2.7M History
Ron Baron, Bamco Inc. (Baron Capital) <0.01% Reduce −56.5% 10,000 $852K History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CYTK's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CYTK insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $47.1M sold by 10 insiders under 10b5-1 plans
  1. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $224K 3,500 shares at $64.01 2.2% of stake
    Traded Oct 20 Filed Oct 20
    ↗
  2. Robert I Blum CEO
    Planned sale
    $472K 7,500 shares at $62.88 2.6% of stake
    Traded Oct 12 Filed Oct 13
    ↗
  3. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $215K 3,500 shares at $61.38 2.2% of stake
    Traded Oct 6 Filed Oct 6
    ↗
  4. Robert I Blum CEO
    Planned sale
    $491K 7,500 shares at $65.46 2.6% of stake
    Traded Sep 28 Filed Sep 28
    ↗
  5. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $239K 3,500 shares at $68.29 2.2% of stake
    Traded Sep 22 Filed Sep 22
    ↗
  6. Robert E Landry Director
    Planned sale
    $72K 1,000 shares at $72.13 11% of stake
    Traded Sep 15 Filed Sep 15
    ↗
  7. Robert I Blum CEO
    Planned sale
    $7.3M 105,426 shares at $69.62
    Traded Sep 14–15 Filed Sep 15
    ↗
  8. Robert E Landry Director
    Planned sale
    $75K 1,000 shares at $74.66 9.8% of stake
    Traded Sep 11 Filed Sep 11
    ↗
  9. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $264K 3,500 shares at $75.46 2.2% of stake
    Traded Sep 8 Filed Sep 8
    ↗
  10. B Lynne Parshall Director
    Planned sale
    $357K 5,000 shares at $71.48 32% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  11. Andrew Callos EVP, Chief Commercial Officer
    Planned sale
    $702K 10,000 shares at $70.24 15% of stake
    Traded Aug 31 Filed Aug 31
    ↗
  12. Robert I Blum CEO
    Planned sale
    $527K 7,500 shares at $70.24 1.9% of stake
    Traded Aug 31 Filed Aug 31
    ↗
  13. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $265K 3,500 shares at $75.82 2.2% of stake
    Traded Aug 18 Filed Aug 18
    ↗
  14. Robert I Blum CEO
    Planned sale
    $576K 7,500 shares at $76.76 1.9% of stake
    Traded Aug 10 Filed Aug 10
    ↗
  15. Andrew Callos EVP, Chief Commercial Officer
    Planned sale
    $1.1M 14,000 shares at $79.88 19% of stake
    Traded Jul 30 Filed Jul 30
    ↗

Also filed in the last 12 months, not counted as buying or selling: 66 option exercises, 48 stock grants, 10 sales to cover taxes, 9 share withholdings for taxes, and 4 gifts.

Congress

2 members of Congress traded CYTK in the last three years: 4 buys and 1 sale. 1 member listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Sep 29 filed Oct 12
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jun 30 filed Jul 2
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Oct 9, 2025 filed Nov 18, 2025
  4. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Jun 17, 2025 filed Aug 13, 2025
  5. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Jun 11, 2025 filed Aug 13, 2025

SEC filings

Recent issuer filings from EDGAR, 6 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 10 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $7.53M $18.47M $88.04M
Net income -$526.24M -$589.53M -$784.96M
Net margin * -6988.6% -3191.1% -891.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.628B $1.11B $0.917B
Total non-current assets * $196.26M $293.73M $507.56M
Total assets $0.824B $1.4B $1.42B
Total current liabilities $102.68M $179.67M $202.45M
Total non-current liabilities * $1.11B $1.36B $1.88B
Total equity -$386.32M -$135.37M -$659.62M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$414.33M -$395.89M -$510.01M
Cash from investing $239.25M -$553.1M $16.67M
Cash from financing $221.32M $930.61M $524.46M
Net change in cash $46.22M -$18.17M $30.4M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.